Top-News
  • Depot
  • Watchlist
  • Glocke

  • Innovent Biologics Inc.

    49,7095 $ +3,2795 $ +7,06%
    In : 42,692 € | 10.09.25 19:16:10 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    ISIN: US45783L1017
    US-Symbol: IVBIY

    Innovent Biologics Inc. News

    28.05.25 - PR Newswire
    Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
    Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with ...
    25.05.25 - PR Newswire
    Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)
    Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM) PR Newswire
    18.05.25 - PR Newswire
    Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation
    Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation PR Newswire
    15.05.25 - PR Newswire
    Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)
    Second Head-​to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver ...
    06.05.25 - PR Newswire
    Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
    Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-​in-class Anti-VEGF and Anti-​Complement ...
    05.05.25 - PR Newswire
    Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
    Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-​in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 PR ...
    29.04.25 - PR Newswire
    Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies
    Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-​in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies PR Newswire
    27.04.25 - PR Newswire
    2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs
    2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-​specific Antibodies and Bispecific ADCs PR Newswire
    25.04.25 - PR Newswire
    Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer
    Innovent Announces NMPA Approval of Limertinib, a Third-​generation EGFR TKI Collaborated with ASK Pharma, for the First-​line Treatment of Lung Cancer PR Newswire
    23.04.25 - PR Newswire
    Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting
    Seven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual Meeting PR Newswire
    26.03.25 - PR Newswire
    Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
    Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting PR Newswire
    26.03.25 - PR Newswire
    Innovent Announces 2024 Annual Results and Business Updates
    Innovent Announces 2024 Annual Results and Business Updates PR Newswire
    23.03.25 - PR Newswire
    Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
    Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-​resistant Ovarian Cancer PR Newswire
    18.03.25 - PR Newswire
    Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
    Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell ...
    14.03.25 - PR Newswire
    China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
    China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease PR Newswire
    02.03.25 - PR Newswire
    Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
    Head-​to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma ...
    23.02.25 - PR Newswire
    NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer
    NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as ...
    16.02.25 - PR Newswire
    Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
    Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer PR ...
    16.01.25 - PR Newswire
    Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
    Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-​generation EGFR TKI for the Treatment of Lung Cancer PR Newswire
    16.01.25 - PR Newswire
    Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference
    Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire

    Newssuche

    Videos

    newspaper
    18:20 Uhr
    Master the Trading!
    In diesem Trading-​Webinar haben wir von A bis Z den Aufbau professionellen Tradings thematisiert und ... Mehr »